Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.

导出 LinkOut

翻译打印收藏纠错

作者： Fernando,Recio ^[1] ; Carly Bess,Scalise ^[2] ; Paul,Loar ^[3] ; Melissa,Lumish ^[4] ; Tara,Berman ^[5] ; Abhinand,Peddada ^[6] ; Ekaterina,Kalashnikova ^[2] ; Samuel,Rivero-Hinojosa ^[2] ; Tricia,Beisch ^[2] ; Brittany,Nicosia ^[2] ; Tiffany,Farmer ^[2] ; Punashi,Dutta ^[2] ; Meenakshi,Malhotra ^[2] ; Adam C,ElNaggar ^[2] ; Minetta C,Liu ^[2] ; Luis,Vaccarello ^[7] ; Robert W,Holloway ^[8]

作者单位： AdventHealth Orlando Gynecologic Oncology, Orlando, FL, USA. ^[1] Natera, Inc, Austin, TX, USA. ^[2] Texas Oncology, Austin, TX, USA. ^[3] Memorial Sloan Kettering Cancer Center, NY, USA. ^[4] Inova Schar Cancer Institute, Fairfax, VA, USA. ^[5] William N. Pennington Cancer Institute, Reno, NV, USA. ^[6] Zangmeister Cancer Center, Columbus, OH, USA. ^[7] AdventHealth Orlando Gynecologic Oncology, Orlando, FL, USA. Electronic address: robhollowaymd@gmail.com. ^[8]

关键词 Circulating tumor DNA/ctDNA Endometrial cancer Risk groups Tumor biomarkers

主题词人类(Humans);女(雌)性(Female);预后(Prognosis);子宫内膜肿瘤(Endometrial Neoplasms);肿瘤复发, 局部(Neoplasm Recurrence, Local)

DOI 10.1016/j.ygyno.2023.12.025

PMID 38262240

发布时间 2024-08-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交